<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <?properties manuscript?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">101525337</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">37346</journal-id>
      <journal-id journal-id-type="nlm-ta">ACS Chem Neurosci</journal-id>
      <journal-id journal-id-type="iso-abbrev">ACS Chem Neurosci</journal-id>
      <journal-title-group>
        <journal-title>ACS chemical neuroscience</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1948-7193</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25746685</article-id>
      <article-id pub-id-type="pmc">4489556</article-id>
      <article-id pub-id-type="doi">10.1021/acschemneuro.5b00010</article-id>
      <article-id pub-id-type="manuscript">NIHMS696525</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Lohr</surname>
            <given-names>Kelly M.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stout</surname>
            <given-names>Kristen A.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dunn</surname>
            <given-names>Amy R.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Minzheng</given-names>
          </name>
          <xref ref-type="aff" rid="A1">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Salahpour</surname>
            <given-names>Ali</given-names>
          </name>
          <xref ref-type="aff" rid="A5">⊥</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guillot</surname>
            <given-names>Thomas S.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">†</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miller</surname>
            <given-names>Gary W.</given-names>
          </name>
          <xref rid="FN1" ref-type="author-notes">*</xref>
          <xref ref-type="aff" rid="A1">†</xref>
          <xref ref-type="aff" rid="A2">‡</xref>
          <xref ref-type="aff" rid="A3">§</xref>
          <xref ref-type="aff" rid="A4">‖</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>†</label>Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, Georgia 30322, United States</aff>
      <aff id="A2"><label>‡</label>Center for Neurodegenerative Diseases, Emory University, Atlanta, Georgia 30322, United States</aff>
      <aff id="A3"><label>§</label>Department of Pharmacology, Emory University, Atlanta, Georgia 30322, United States</aff>
      <aff id="A4"><label>‖</label>Department of Neurology, Emory University, Atlanta, Georgia 30322, United States</aff>
      <aff id="A5"><label>⊥</label>Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada</aff>
      <author-notes>
        <corresp id="FN1"><label>*</label>Corresponding Author: Mailing address: 1518 Clifton Road, Rollins School of Public Health, Atlanta, GA 30322, USA. Phone: 404-712-8582. <email>gary.miller@emory.edu</email></corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>24</day>
        <month>6</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>09</day>
        <month>3</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>20</day>
        <month>5</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>02</day>
        <month>7</month>
        <year>2015</year>
      </pub-date>
      <volume>6</volume>
      <issue>5</issue>
      <fpage>790</fpage>
      <lpage>799</lpage>
      <!--elocation-id from pubmed: 10.1021/acschemneuro.5b00010-->
      <permissions>
        <copyright-statement>© XXXX American Chemical Society</copyright-statement>
      </permissions>
      <abstract>
        <p id="P1">The psychostimulant methamphetamine (METH) is highly addictive and neurotoxic to dopamine terminals. METH toxicity has been suggested to be due to the release and accumulation of dopamine in the cytosol of these terminals. The vesicular monoamine transporter 2 (VMAT2; <italic>SLC18A2</italic>) is a critical mediator of dopamine handling. Mice overexpressing VMAT2 (VMAT2-HI) have an increased vesicular capacity to store dopamine, thus augmenting striatal dopamine levels and dopamine release in the striatum. Based on the altered compartmentalization of intracellular dopamine in the VMAT2-HI mice, we assessed whether enhanced vesicular function was capable of reducing METH-induced damage to the striatal dopamine system. While wildtype mice show significant losses in striatal levels of the dopamine transporter (65% loss) and tyrosine hydroxylase (46% loss) following a 4 × 10 mg/kg METH dosing regimen, VMAT2-HI mice were protected from this damage. VMAT2-HI mice were also spared from the inflammatory response that follows METH treatment, showing an increase in astroglial markers that was approximately one-third of that of wildtype animals (117% vs 36% increase in GFAP, wildtype vs VMAT2-HI). Further analysis also showed that elevated VMAT2 level does not alter the ability of METH to increase core body temperature, a mechanism integral to the toxicity of the drug. Finally, the VMAT2-HI mice showed no difference from wildtype littermates on both METH-induced conditioned place preference and in METH-induced locomotor activity (1 mg/kg METH). These results demonstrate that elevated VMAT2 protects against METH toxicity without enhancing the rewarding effects of the drug. Since the VMAT2-HI mice are protected from METH despite higher basal dopamine levels, this study suggests that METH toxicity depends more on the proper compartmentalization of synaptic dopamine than on the absolute amount of dopamine in the brain.</p>
        <p id="P2">
<graphic xlink:href="nihms696525u1.jpg" position="float" orientation="portrait"/></p>
      </abstract>
      <kwd-group>
        <kwd>Methamphetamine</kwd>
        <kwd>VMAT2</kwd>
        <kwd>vesicle</kwd>
        <kwd>neurodegeneration</kwd>
        <kwd>inflammation</kwd>
        <kwd>dopamine</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>

